Incretin Atlas › Trials › REWIND
REWIND
Dulaglutide · T2D, broad CV risk
Design
- Molecule(s)
- Dulaglutide
- Population
- T2D, broad CV risk
- Official title
- Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
- Sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Registry status
- completed · 2011-07 → 2018-08
- Participants
- 9901
- Registry
- NCT01394952
Cardiovascular and kidney outcomes
REWIND dulaglutide 1.5 mg vs placebo · T2D, broad CV risk · n = 9901 · 2019 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 3-point MACE primary First occurrence of non-fatal MI, non-fatal stroke, or death from cardiovascular causes (including unknown causes) | 0.88 | 0.79–0.99 | 594 vs 663 | verified |
| Cardiovascular death Cardiovascular death (includes deaths of unknown cause) | 0.91 | 0.78–1.06 | 317 vs 346 | verified |
| All-cause death Death from any cause | 0.90 | 0.80–1.01 | 536 vs 592 | verified |
| Myocardial infarction Myocardial infarction (fatal or non-fatal) | 0.96 | 0.79–1.15 | 223 vs 231 | verified |
| Stroke Stroke (fatal or non-fatal) | 0.76 | 0.62–0.94 | 158 vs 205 | verified |
| Hospitalisation for heart failure Hospital admission for heart failure or urgent visit requiring therapy | 0.93 | 0.77–1.12 | 213 vs 226 | verified |
| Kidney composite Composite renal outcome: new macroalbuminuria (UACR >33.9 mg/mmol), sustained eGFR decline of 30% or more from baseline, or chronic renal replacement therapy | 0.85 | 0.77–0.93 | 848 vs 970 | verified |
| Retinopathy complications Eye outcome (clinical diabetic retinopathy): photocoagulation, anti-vascular endothelial growth factor therapy, or vitrectomy (component of the composite microvascular outcome) | 1.24 | 0.92–1.68 | 95 vs 76 | verified |
| Hospitalisation for unstable angina Hospital admission for unstable angina | 1.14 | 0.84–1.54 | 88 vs 77 | verified |
Verbatim quotes (9)
- 3-point MACE · Results, paragraph 3; Table 2
the primary composite outcome occurred in 594 (12·0%) participants ... assigned to dulaglutide and 663 (13·4%) ... assigned to placebo (HR 0·88, 95% CI 0·79–0·99; p=0·026)
- Cardiovascular death · Table 2
Cardiovascular death† 317 (6·4%) 1·22 346 (7·0%) 1·34 0·91 (0·78–1·06) 0·21
- All-cause death · Summary, Findings; Table 2
All-cause mortality did not differ between groups (536 [10·8%] in the dulaglutide group vs 592 [12·0%] in the placebo group; HR 0·90, 95% CI 0·80–1·01; p=0·067)
- Myocardial infarction · Table 2
Myocardial infarction 223 (4·5%) 0·87 231 (4·7%) 0·91 0·96 (0·79–1·15) 0·63
- Stroke · Table 2
Stroke 158 (3·2%) 0·61 205 (4·1%) 0·81 0·76 (0·62–0·94) 0·010
- Hospitalisation for heart failure · Table 2
Hospital admission for heart failure or urgent visit 213 (4·3%) 0·83 226 (4·6%) 0·89 0·93 (0·77–1·12) 0·46
- Kidney composite · Table 2
Renal outcome§ 848 (17·1%) 3·47 970 (19·6%) 4·07 0·85 (0·77–0·93) 0·0004
- Retinopathy complications · Table 2: Primary and secondary outcomes (footnote ‡)
Eye outcome‡ 95 (1·9%) 0·37 76 (1·5%) 0·30 1·24 (0·92–1·68) 0·16
- Hospitalisation for unstable angina · Table 2: Primary and secondary outcomes
Hospital admission for unstable angina 88 (1·8%) 0·34 77 (1·6%) 0·30 1·14 (0·84–1·54) 0·41
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: REWIND. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/rewind/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.